Keynote Speaker

Sriram Subramaniam, Ph.D.

Senior Investigator

Laboratory of Cell Biology

National Cancer Institute

Recent breakthroughs in the field of cryo-electron microcopy (cryo-EM) provide new prospects for determination of the structures of a variety of medically important macromolecular assemblies. The prospect that the determination of protein structures at atomic resolution will no longer be limited by size, or by the need for crystallization represents a significant and exciting horizon in structural biology. 

In my lecture, I will discuss the broader context of the development of cryo-EM methods for studying protein complexes, viruses and cells, and provide an overview of current progress and future directions as they relate to the development of improved therapeutic agents. 



Anasuya Adibhatla, Excillum Inc.

MetalJet Source for Time Resolved X- ray Diffraction and Scattering

Dirk Brussiere, Novartis Institute for BioMedical Research

Discovery and Structure-Based Optimization of Novel Allosteric Inhibitors Targeting the Epigenetic Methyltransferase PRC2

Phillip Chamberlain, Celgene

Targeted protein degradation: Expanding the druggable genome with cereblon modulators

Melanie Cocco, UC Irvine Department of Molecular Biology and Biochemistry

Agents to block the neurite outgrowth inhibitor (NOGO) inspired by the structure

José Duca, Novartis Institute for BioMedical Research

Exploring Molecular Dynamics Simulations of Membranes in Drug Discovery

Andreas Frank, Novartis Institute for BioMedical Research

Broadband Fluorine-NMR for the Efficient Screening of Large and Diverse Fragment Libraries

David Hargreaves, AstraZeneca

Discovery and utilisation of an antibody enabled structural system to support the structurally challenging target Mcl-1

Seth Harris, Genentech

Navigating a dozen binding sites: the immunoproteasome and structure-based drug design

Joseph Ho, Eli Lilly

Structural basis for GPR40 allosteric agonism and incretin stimulation

Xin Huang, Amgen

Crystal structures of human glycine receptor alpha3 bound to a novel class of analgesic potentiators

Sarah Hymowitz, Genentech

Enabling kinases for structure-based drug design and mechanism of action studies

Jayasankar Jasti, Pfizer

Structural Biology Studies to aid discovery of selective Leucine-rich Repeat Kinase 2 (LRRK2) Inhibitors

Chris Koth, Genentech

Structural basis for selective small molecule antagonism of the LPS transporter MsbA

Eric Lansdon, Gilead Sciences Inc.

Finding Selectivity in Type I Kinase Inhibitors

Charles Lesburg, Merck Research Laboratories

Making sense of legacy data to inform decisions today - tools to enable rapid integrated access to macromolecular structural data

Doug Marcotte, Biogen

Lock and Chop: A novel method for the generation of a PICK1 PDZ domain and piperidine-based inhibitor co-crystal structure

Steve McCloskey, Nanome Inc.

Next Generation Molecular Visualization, Collaboration, and Design

Andrew Proudfoot, Novartis Institute for BioMedical Research

High Confidence Protein-Ligand Complex Modeling by NMR-Guided Docking Enables Early Hit Optimization

James P. Rizzi, Peloton Therapeutics

A SBDD approach for the discovery of PT2385, a first-in-class HIF-2alpha inhibitor for the treatment of renal cell carcinoma

Gyorgy Snell, Takeda California

Leveraging Structural Biology for Large Molecule Discovery: Exploring Antigen-Antibody interfaces in atomic detail

Giovanna Scapin, Merck

Structure of the Insulin Receptor in Complex with Insulin using Single Particle CryoEM Analysis

Pedro Serrano, Takeda California

NMR in Takeda's drug discovery pipeline

Satoshi Sogabe, Axcelead Drug Discovery Partners Inc.

Structural investigation of ligand binding sites by X-ray crystallography

Stefan Steinbacher, Proteros Biostructures GmbH

Case Study on CDK8/CyCC - Structure guided fragment evolution towards long residence time

Andrew Turnbull, Cancer Research UK Therapeutic Discovery Laboratories

Molecular basis of USP7 inhibition by selective small-molecule inhibitors

Weiru Wang, Genentech

Developing Structural Hypothesis of Crenezumab’s Mechanism of Action

Cheng Zhang, University of Pittsburgh

Structure and pharmacology of two chemoattractant GPCRs in inflammation